Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 317

1.
3.

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM.

Virology. 2001 Jul 5;285(2):193-203.

5.

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC.

Antimicrob Agents Chemother. 2000 Mar;44(3):794-7.

6.

Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.

Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA.

J Antimicrob Chemother. 2010 Nov;65(11):2291-9. doi: 10.1093/jac/dkq338. Epub 2010 Sep 18.

PMID:
20852269
8.
9.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.

J Virol. 2001 Jun;75(11):4999-5008.

10.
12.

A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.

J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10.

14.
15.

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.

Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):136-44.

PMID:
9052722
17.

[Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].

Cao YL, Li SX, Chen H, Guo Y.

Yao Xue Xue Bao. 2009 Apr;44(4):355-61. Chinese.

PMID:
19545051
19.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.

20.

Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.

Corona A, Meleddu R, Esposito F, Distinto S, Bianco G, Masaoka T, Maccioni E, Menéndez-Arias L, Alcaro S, Le Grice SF, Tramontano E.

PLoS One. 2016 Jan 22;11(1):e0147225. doi: 10.1371/journal.pone.0147225. eCollection 2016.

Supplemental Content

Support Center